Part 5/Chapter 12/16-min read

Venous Thromboembolism

DVT and PE diagnosis, anticoagulation strategies, and thrombolytic therapy

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·20 sections · 40 references

Background

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially fatal cardiovascular condition requiring structured diagnostic pathways, early risk stratification, and prompt anticoagulation for most patients to mitigate the risk of early recurrence.

VTE outcomes depend on:

  • Accurate pretest probability assessment with selective use of D-dimer and imaging to avoid missed PE while limiting unnecessary computed tomography pulmonary angiography (CTPA).
  • Appropriate anticoagulant selection (direct oral anticoagulants (DOACs) for most, as they reduce recurrence and mortality compared to traditional therapies; warfarin for high-risk antiphospholipid syndrome; low-molecular-weight heparin (LMWH) often preferred in pregnancy).
  • Timely reperfusion for high-risk PE and selected severe DVT (e.g., threatened limb, phlegmasia).

Long-term sequelae include post-thrombotic syndrome (13post-thrombotic syndrome) after DVT and chronic thromboembolic pulmonary hypertension (CTEPH) after PE; persistent symptoms warrant structured follow-up and referral.

See also 13CVI for chronic venous obstruction/reflux care and 3Chapter 3 for imaging principles.

Virchow's Triad

Virchow's triad

  1. Venous stasis (immobility, hospitalization, surgery, trauma, paralysis, long-distance travel, heart failure). Stasis-induced venous valve hypoxia is a recognized mechanism for thrombus initiation, even in the absence of overt vessel wall damage .
  2. Endothelial injury (trauma, surgery, central venous catheters, prior thrombosis). High-energy trauma, such as traumatic spine fractures, significantly increases the risk of concomitant venous thromboembolism (VTE) through direct vessel damage and associated immobility .
  3. Hypercoagulability
  • Inherited: factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein C/S deficiency.
  • Acquired: malignancy, pregnancy/postpartum, estrogen therapy, antiphospholipid syndrome (APS), inflammatory states, and vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS) .

Surgical venous thromboembolism (VTE) risk assessment

Validated risk assessment models (e.g., Caprini) help stratify perioperative VTE risk and guide prophylaxis intensity and duration in surgical patients.

Educational summary

Caprini

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

Pathophysiology

  • Thrombosis occurs when the balance between coagulation and fibrinolysis shifts toward clot formation.
  • Most lower limb DVTs begin in calf veins, propagating proximally.
  • Pulmonary embolism (PE) occurs when thrombus embolizes to pulmonary arteries, leading to increased pulmonary vascular resistance, right ventricular strain, and hypoxemia.
  • Long-term sequelae: venous valve destruction leads to reflux, venous hypertension, and post-thrombotic syndrome (PTS).

DVT

  • Unilateral swelling, pain, erythema, warmth.
  • Homan's sign (calf pain on dorsiflexion) – non-specific.
  • Proximal 12VTE (iliofemoral) → higher 12VTE risk.
  • Long-term sequelae include post-thrombotic syndrome (13PTS) .
  • Clinically unsuspected (incidental) DVT is increasingly recognized, particularly in pediatric and neonatal populations, necessitating standardized definitions and clinical assessment .

PE

  • Dyspnea, pleuritic chest pain, hemoptysis.
  • Tachypnea, tachycardia, hypoxemia.
  • Massive 12VTE can cause hypotension, shock, syncope, and sudden death.

Clinical prediction

Why clinical prediction matters

Clinical prediction rules help determine when D-dimer can safely exclude venous thromboembolism (VTE) and when definitive imaging is required (particularly for high pretest probability).

Suspected deep vein thrombosis (DVT)

  • Use a validated score (e.g., Wells DVT) to classify pretest probability.
  • Low pretest probability:
    • Obtain D-dimer; if negative, DVT is excluded without imaging.
    • If D-dimer is positive, perform compression ultrasound (CUS).
  • Intermediate/high pretest probability:
    • Proceed directly to CUS; do not rule out with D-dimer alone.

Educational summary

Wells DVT

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

Suspected pulmonary embolism (PE)

  • Use Wells PE or Geneva score (or an ED protocol), then apply D-dimer/imaging accordingly.
  • The YEARS strategy can reduce CTPA utilization while maintaining safety when applied to appropriate populations.

Educational summary

Wells PE

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

Pregnancy

A pregnancy-adapted YEARS strategy can safely reduce imaging in pregnant patients with suspected PE when combined with D-dimer thresholds and structured assessment.

Educational summary

PESI

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

Laboratory

D-dimer (rule-out testing)

D-dimer is most useful in patients with low or intermediate pretest probability; a negative result can safely exclude deep vein thrombosis (DVT)/pulmonary embolism (PE) without imaging in properly selected patients.

Age-adjusted threshold

For outpatients ≥50 years, age-adjusted D-dimer (age × 10 μg/L FEU) increases specificity and reduces unnecessary imaging while maintaining safety.

Algorithm-specific thresholds

Some diagnostic strategies (e.g., YEARS and pregnancy-adapted YEARS) incorporate variable D-dimer thresholds based on specific clinical items, further reducing imaging in selected populations.

Practical notes

  • Confirm whether your lab reports FEU vs DDU; thresholds differ by assay.
  • A positive D-dimer is not diagnostic and should trigger imaging based on probability category.

Imaging

deep vein thrombosis (DVT) imaging

Compression ultrasound (CUS) is the first-line imaging test for suspected lower-extremity DVT.

  • Proximal CUS (common femoral through popliteal) is widely used.
  • If initial proximal CUS is negative but suspicion persists, repeat CUS (serial ultrasound) is an accepted strategy, particularly when anticoagulation is being withheld.

For suspected iliofemoral DVT with nondiagnostic CUS (e.g., obesity, high inguinal disease), consider CT or MR venography or focused iliac duplex in experienced labs.

pulmonary embolism (PE) imaging

Computed tomography pulmonary angiography (CTPA) is the most common confirmatory test for PE; PIOPED II demonstrated high diagnostic performance in appropriate clinical contexts.

V/Q scanning and pregnancy

When contrast is contraindicated or in pregnancy, V/Q scanning is often preferred when the chest radiograph is normal; structured algorithms (including pregnancy-adapted YEARS) can reduce imaging while maintaining safety.

Echocardiography

Bedside echocardiography is not a rule-out test for PE, but is valuable in suspected high-risk PE to assess right ventricular dysfunction and guide urgent reperfusion decisions.

Risk stratification in PE

Wells Score for pulmonary embolism (PE) can be used to determine pretest probability before imaging:

Educational summary

Wells PE

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

After clinical probability assessment:

  • High-risk PE: shock or persistent hypotension.
  • Intermediate-risk PE: normotensive with RV dysfunction and/or positive cardiac biomarkers (intermediate-high if both present; intermediate-low if one present).
  • Low-risk PE: normal hemodynamics, normal RV, negative biomarkers; consider outpatient care in patients with low PESI/sPESI scores .

Anticoagulation (cornerstone therapy)

Treatment phases

Anticoagulation for acute deep vein thrombosis (DVT)/pulmonary embolism (PE) is typically organized into:

  • Initial phase (first days): prevent early extension/embolization.
  • Primary treatment (first 3 months): treat the index event.
  • Extended phase (beyond 3 months): prevent recurrence in selected patients.

First-line agents (most patients)

  • DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first-line for most hemodynamically stable DVT/PE patients without contraindications.

Cancer-associated venous thromboembolism (VTE)

  • DOACs are effective alternatives to LMWH (edoxaban; apixaban), but consider bleeding risk (especially GI/GU mucosal tumors) and drug–drug interactions.

When warfarin (VKA) is preferred

  • High-risk APS (especially triple-positive): warfarin is preferred due to increased thrombotic events seen with rivaroxaban in this population.
  • Severe renal impairment: UFH with transition to warfarin is often used; DOAC use may be limited by labeling and evidence constraints.

Pregnancy

  • Use LMWH during pregnancy and postpartum; avoid DOACs and warfarin in pregnancy.

Duration of Anticoagulation Therapy

Core duration principles

  • Provoked venous thromboembolism (VTE) (major transient risk factor such as surgery/major trauma): 3 months is generally sufficient.
  • Unprovoked VTE: treat for at least 3 months, then reassess recurrence vs bleeding risk; many patients benefit from extended therapy if bleeding risk is not high.
  • Cancer-associated VTE: anticoagulate for a minimum of 6 months, and continue while cancer is active or treatment ongoing.

Extended-phase options

Reduced-dose DOAC strategies are effective for extended secondary prevention (e.g., rivaroxaban 10 mg daily after initial treatment in appropriate patients).

Identifying low-risk patients after unprovoked VTE

In selected patients (notably some women) with unprovoked VTE, validated rules such as HERDOO2 can identify a subgroup with sufficiently low recurrence risk to consider stopping anticoagulation after completing primary treatment.

Table 11.3TreatmentDuration of Anticoagulation by Clinical Scenario
Provoked by surgery/major trauma
**Duration**
3 months
**Notes**
Major transient risk factor
Provoked by a persistent risk factor
**Duration**
Extended while risk persists
**Notes**
Reassess periodically
Unprovoked, first event
**Duration**
3 months minimum, then reassess
**Notes**
Consider extended if bleeding risk acceptable
Unprovoked, recurrent
**Duration**
Indefinite
**Notes**
Unless high bleeding risk
Cancer-associated
**Duration**
≥6 months + while active
**Notes**
Continue until remission/off therapy
High-risk APS
**Duration**
Indefinite
**Notes**
Prefer warfarin

Advanced and Endovascular Therapies

General principle

Most deep vein thrombosis (DVT)/pulmonary embolism (PE) patients are treated with anticoagulation alone; advanced therapies are reserved for limb-threatening DVT or hemodynamically significant PE, or carefully selected intermediate-risk scenarios.

Acute DVT thrombus removal (selected patients)

  • Indications (typical)
  • Acute iliofemoral DVT with severe symptoms, low bleeding risk, good functional status, and anticipated meaningful benefit (symptom relief and/or PTS reduction).
  • Phlegmasia or threatened limb (urgent).
  • Catheter-directed thrombolysis (CDT) / pharmacomechanical CDT
  • CAVENT suggested reduced PTS in iliofemoral DVT with CDT vs anticoagulation alone.
  • ATTRACT showed no overall reduction in PTS with pharmacomechanical CDT, but may improve early symptom burden in selected iliofemoral subgroups; bleeding risk must be considered.
  • Mechanical thrombectomy without lytic

May be considered when thrombolysis is contraindicated, recognizing that high-quality comparative data remain limited; patient selection and institutional expertise are critical.

Acute PE reperfusion therapies

  • Systemic thrombolysis

Recommended for high-risk (massive) PE with shock or persistent hypotension unless contraindicated.

  • Catheter-directed thrombolysis (PE)

Lower-dose thrombolysis strategies (including ultrasound-assisted systems) can improve RV parameters with potentially reduced bleeding compared with systemic dosing in selected patients.

  • Catheter-directed mechanical thrombectomy (PE)

Prospective device studies in intermediate-risk PE demonstrate improvements in RV/LV ratio and clinical parameters without thrombolytic use in many patients.

  • FlowTriever (FLARE).
  • Indigo aspiration (EXTRACT-PE).
  • Surgical embolectomy / ECMO

Consider for high-risk PE when thrombolysis is contraindicated or unsuccessful, ideally via a multidisciplinary PE response pathway.

Inferior vena cava (IVC) filters

  • Primary indication

Acute proximal DVT and/or PE with an absolute contraindication to anticoagulation, or major bleeding requiring interruption when thrombotic risk is high.

  • Evidence and harms

Permanent filters reduced PE but increased DVT in PREPIC long-term follow-up. In patients who can receive anticoagulation, adding a retrievable filter did not reduce recurrent PE in PREPIC2.

  • Retrieval

When a filter is placed, plan retrieval as soon as the contraindication resolves and anticoagulation can be resumed; structured follow-up systems improve retrieval rates and reduce long-term complications.

Follow-up and Long-Term Management

Compression and early recovery after deep vein thrombosis (DVT)

Routine elastic compression stockings are not recommended solely to prevent PTS after proximal DVT, based on randomized trial evidence; however, compression may be used for symptomatic edema/pain with individualized fitting and reassessment.

Encourage early ambulation once anticoagulated and clinically stable.

Post-thrombotic syndrome (PTS)

PTS is a common sequela after proximal DVT and should be assessed in symptomatic patients (typically starting 3–6 months after the index event) using validated clinical scales (e.g., Villalta).

Management options (stepwise):

  • Optimize anticoagulation adherence and address persistent provoking factors.
  • Compression therapy for symptoms (edema, heaviness) and supervised exercise/rehabilitation.
  • Evaluate for chronic venous obstruction (e.g., iliofemoral outflow obstruction) in refractory, lifestyle-limiting symptoms; selected patients may benefit from endovascular venous reconstruction (e.g., iliac venous stenting) in experienced centers.

See 13CVI for chronic venous obstruction/reflux strategies.

pulmonary embolism (PE) follow-up and CTEPH

Patients with persistent dyspnea, exercise intolerance, or right heart strain after acute PE should be evaluated for chronic thromboembolic disease/CTEPH (e.g., echocardiography, referral pathways).

Imaging surveillance

Routine surveillance duplex ultrasound after treated DVT is not recommended in asymptomatic patients; repeat imaging is generally reserved for recurrent symptoms, anticoagulation decisions, or suspected extension/recurrence.

Guidelines

Major contemporary guidance (selected)

  • ESC 2019 Acute PE guideline
    • PE risk stratification (high-, intermediate-, low-risk), PESI/sPESI, outpatient management for selected low-risk patients, and reperfusion recommendations.
  • ESVS 2021 Venous thrombosis guideline
    • Diagnostic pathways for DVT, selection for early thrombus removal in iliofemoral DVT, and long-term sequelae considerations.
  • CHEST 2021 VTE antithrombotic guideline update
    • Anticoagulant selection and duration (initial/primary/extended phase) with emphasis on DOACs for most patients.
  • ASH 2018 VTE diagnosis guidelines
    • Evidence-based DVT and PE diagnostic algorithms (clinical probability, D-dimer strategies, and imaging).
  • SIR 2020 IVC filter guideline
    • Indications, complications, and retrieval/follow-up systems.

Tables

Table 12.1GuidelinesPractical diagnostic pathways for suspected DVT and PE (simplified)
Suspected DVT, low pretest probability
**Next step**
D-dimer
**Key point**
If negative, DVT excluded without imaging
Suspected DVT, D-dimer positive or higher probability
**Next step**
CUS (± serial CUS)
**Key point**
Repeat ultrasound if initial proximal CUS negative but suspicion persists
Suspected PE, low/intermediate probability
**Next step**
D-dimer strategy (age-adjusted or algorithmic)
**Key point**
Use validated strategies to reduce unnecessary CTPA
Suspected PE, high probability
**Next step**
CTPA (or alternative if contraindicated)
**Key point**
Do not rely on negative D-dimer alone

Table 12.2TreatmentWhen to consider advanced therapies or IVC filters (high-yield indications)
Systemic thrombolysis (PE)
**Best-supported indication**
High-risk PE with shock/hypotension
**Notes**
Bleeding risk must be weighed
Catheter-directed PE therapy
**Best-supported indication**
Selected intermediate/high-risk PE
**Notes**
Lower lytic dose options exist
CDT / pharmacomechanical CDT (DVT)
**Best-supported indication**
Selected acute iliofemoral DVT with severe symptoms/low bleed risk
**Notes**
ATTRACT: no overall PTS reduction; selection matters
IVC filter
**Best-supported indication**
Absolute contraindication to anticoagulation in acute VTE
**Notes**
PREPIC2: no routine benefit when anticoagulation feasible; retrieve early

Management of isolated distal (calf) DVT and role of serial ultrasound

Isolated distal (calf) deep vein thrombosis (DVT) requires individualized management. Anticoagulation is indicated for patients with severe symptoms, high risk of thrombus extension, or significant prothrombotic risk factors. For low-risk patients without these features, serial duplex ultrasound surveillance at 1 week and 2 weeks is an acceptable alternative to immediate anticoagulation. Management decisions should incorporate patient-centered bleeding risk assessment and shared decision-making .

Outpatient management of low-risk PE (PESI/sPESI, Hestia)

Selected patients with low-risk pulmonary embolism may be safely managed in the outpatient setting using validated risk stratification tools. The Pulmonary Embolism Severity Index (PESI) and simplified PESI (sPESI) identify candidates for outpatient therapy, with a score of 0 on sPESI indicating very low 30-day mortality risk. Exclusion criteria for outpatient management include hemodynamic instability, hypoxemia requiring supplemental oxygen, major comorbidities precluding safe home care, and social factors limiting adherence or follow-up. Patients selected for outpatient therapy require close follow-up within 24-72 hours and clear return precautions. The Hestia criteria provide an alternative validated approach to patient selection. Current ESC guidelines support outpatient management in appropriately selected low-risk patients .

Cancer-associated thrombosis: DOACs vs LMWH and GI/GU bleeding risk

Cancer-associated thrombosis presents unique management challenges. Key randomized controlled trials have demonstrated that direct oral anticoagulants (DOACs) are noninferior to low-molecular-weight heparin (LMWH) for cancer-associated venous thromboembolism (VTE). The HOKUSAI-VTE Cancer trial showed edoxaban to be noninferior to dalteparin but with increased gastrointestinal bleeding in patients with gastrointestinal malignancies. The CARAVAGGIO trial found apixaban noninferior to dalteparin with similar bleeding rates, including in gastrointestinal and genitourinary cancers. Selection between DOAC and LMWH therapy should consider: tumor type and location (particularly gastrointestinal and genitourinary cancers with mucosal involvement), baseline thrombocytopenia or bleeding risk, significant drug-drug interactions with chemotherapy, patient preference, and cost. For patients with gastrointestinal or genitourinary cancers at high risk for mucosal bleeding, LMWH may be preferred, though apixaban appears to have a favorable safety profile .

Anticoagulation in special populations (pregnancy, severe renal impairment, antiphospholipid syndrome)

Anticoagulation in special populations requires tailored approaches. Pregnancy: LMWH is the preferred anticoagulant throughout pregnancy and the postpartum period, as DOACs and warfarin are contraindicated due to teratogenicity. Compression ultrasonography is the first-line imaging modality for suspected deep vein thrombosis (DVT). For suspected pulmonary embolism (PE), ventilation-perfusion scanning is preferred when chest radiograph is normal; CTPA may be used when V/Q is unavailable or nondiagnostic, with consideration of fetal and maternal radiation exposure. Severe renal impairment: In patients with creatinine clearance <30 mL/min, DOACs are generally contraindicated or require substantial dose reduction with uncertain efficacy. Unfractionated heparin with transition to warfarin is the preferred approach, though LMWH with anti-Xa monitoring may be considered with caution. Antiphospholipid syndrome (APS): Vitamin K antagonists (warfarin) remain the preferred anticoagulant for high-risk APS, particularly in patients with triple-positive antibody status (lupus anticoagulant, anti-cardiolipin, and anti-β2 glycoprotein I antibodies), as DOACs have shown increased thrombotic events in this population .

Evaluation after unprovoked VTE (occult cancer screening)

The optimal approach to cancer screening after unprovoked venous thromboembolism (VTE) remains an area of clinical uncertainty. Current evidence supports limited age-appropriate cancer screening rather than routine extensive imaging . The SOME (Screening for Occult Malignancy in patients with idiopathic venous thromboembolism) trial demonstrated that routine computed tomography (CT) imaging of the abdomen and pelvis does not improve cancer detection rates or patient outcomes compared to standard age-appropriate screening in patients with unprovoked VTE. The incidence of occult malignancy is estimated at approximately 4% to 5% within the first year following the VTE event. Therefore, the recommended approach consists of: comprehensive history and physical examination, basic laboratory tests (complete blood count (CBC), chemistry), and age-appropriate cancer screening (colonoscopy, mammography, Pap smear, prostate-specific antigen (PSA)) as per standard guidelines. Extensive imaging or invasive testing should be reserved for patients with abnormal findings on initial evaluation or specific clinical suspicion .

References

  1. 1.
    Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
    PubMed-indexed article2020

    Recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range, and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.

    PubMedOpen PDF
  2. 2.
    Eischer L. The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2025. PMID: 41624235.
    PubMed-indexed articleMeta-analysis / systematic review2025
    PubMedDOI
  3. 3.
    Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603.
    PubMed-indexed article2019

    New ESCardio Guidelines for the Diagnosis and Management of Acute PulmonaryEmbolism developed in collaboration with EuroRespSoc are available.

    PubMedOpen PDF
  4. 4.
    Kakkos SK, Gohel M, Baekgaard N, et al. Editor's Choice — European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82.
    PubMed-indexed articleClinical practice guideline2021
    PubMedDOIOpen PDF
  5. 5.
    Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474.
    PubMed-indexed article2015

    Venous thromboembolism includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism, which is associated with reduced survival, substantial health-care costs, and a high rate of recurrence.

    PubMedOpen PDF
  6. 6.
    Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618-3731.
    PubMed-indexed articleClinical practice guideline2022
    PubMedDOIOpen PDF
  7. 7.
    Kahn SR, et al. Post-thrombotic syndrome. *Blood*. 2014;123:3972–80. PubMed. Venous sequelae.
    PubMed-indexed article2014

    This scientific statement is to provide an up-to-date overview of the postthrombotic syndrome (PTS), a frequent, chronic complication of deep venous thrombosis (DVT), and to provide practical recommendations for its optimal prevention, diagnosis, and management.

    PubMedDOIOpen PDF
  8. 8.
    Kotokey UK. Modernising Acute PE and VTE Management: Meta-Analysis of Newer Anticoagulants Versus Traditional Therapy on Recurrence and Mortality. Heart Lung Circ. 2025. PMID: 41206237.
    PubMed-indexed articleMeta-analysis / systematic review2025
    PubMedDOI
  9. 9.
    Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608.
    PubMed-indexed articleClinical practice guideline2021
    PubMedDOI
  10. 10.
    van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390:289-297.
    PubMed-indexed article2017

    Pulmonary embolism was safely excluded by the YEARS diagnostic algorithm in patients with suspected pulmonary emblism, and the main advantage of the YEARs algorithm in the authors' patients is the absolute 14% decrease of CTPA examinations in all ages and across several relevant subgroups.

    PubMedDOI
  11. 11.
    Murtada D et al. Traumatic spine fractures and concomitant venous thromboembolism: A systematic review. World Neurosurg X. 2024. PMID: 39399353.
    PubMed-indexed articleMeta-analysis / systematic review2024
    PubMedDOI
  12. 12.
    Shaydakov ME et al. Venous valve hypoxia as a possible mechanism of deep vein thrombosis: a scoping review. Minerva Med. 2024. PMID: 38864688.
    PubMed-indexed articleMeta-analysis / systematic review2024
    PubMedDOI
  13. 13.
    Waqar U et al. Thrombosis with Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review. Clin Appl Thromb Hemost. 2026. PMID: 34907794.
    PubMed-indexed articleMeta-analysis / systematic review2026
    PubMedDOI
  14. 14.
    Betensky M et al. Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost. 2022. PMID: 35570328.
    PubMed-indexed articleMeta-analysis / systematic review2022
    PubMedDOI
  15. 15.
    Kearon C, et al. Antithrombotic therapy for VTE: CHEST Guidelines. *Chest*. 2016. PubMed
    PubMed-indexed article2016

    Recommendations on 12 topics that were in the 9th edition of these guidelines are updated, and 3 new topics are addressed.

    PubMedDOI
  16. 16.
    Le Gal G, Righini M, Roy PM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of pulmonary embolism. Blood Adv. 2018;2(22):3317-3359.
    PubMed-indexed articleClinical practice guideline2018

    These evidence-based guidelines are intended to support patients, clinicians, and health care professionals in VTE diagnosis by recommending using D-dimer as the initial test and research is needed on new diagnostic modalities and on clinical decision rules for patients with suspected recurrent VTE.

    PubMedDOIOpen PDF
  17. 17.
    van der Pol LM, Tromeur C, Bistervels IM, et al. Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. N Engl J Med. 2019;380:1139-1149.
    PubMed-indexed article2019
    PubMedDOI
  18. 18.
    Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-1124.
    PubMed-indexed article2014

    The combination of pretest clinical probability assessment with age-adjusted D-dimer cutoff was associated with a larger number of patients in whom PE could be considered ruled out with a low likelihood of subsequent clinical venous thromboembolism.

    PubMedOpen PDF
  19. 19.
    Stein PD, Fowler SE, Goodman LR, et al. PIOPED II. N Engl J Med. 2006;354(22):2317-2327.
    PubMed-indexed article2006

    In patients with suspected pulmonary embolism, multidetector CTA-CTV has a higher diagnostic sensitivity than does CTA alone, with similar specificity, and additional testing is necessary when the clinical probability is inconsistent with the imaging results.

    PubMedOpen PDF
  20. 20.
    Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041-1046.
    PubMed-indexed article2005

    The prediction rule is based on 11 simple patient characteristics that were independently associated with mortality and stratifies patients with pulmonary embolism into five severity classes, with 30-day mortality rates of 0-1.6%.

    PubMedOpen PDF
  21. 21.
    Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index (sPESI). J Thromb Haemost. 2010;8(4):620-626.
    PubMed-indexed article2010

    This review summarizes currently available information on selected aspects of floral structure and function and concludes that changes in the homeotic control of floral organ identity may have had a profound impact on floral structure in several disparate lineages in the Annonaceae.

    PubMed
  22. 22.
    Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer (CARAVAGGIO). N Engl J Med. 2020;382(17):1599-1607.
    PubMed-indexed article2020

    Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding.

    PubMedOpen PDF
  23. 23.
    Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk antiphospholipid syndrome (TRAPS): a randomized trial. Blood. 2018;132(13):1365-1371.
    PubMed-indexed articleRandomized controlled trial2018

    The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

    PubMedDOIOpen PDF
  24. 24.
    Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism (Hokusai-VTE Cancer). N Engl J Med. 2018;378(7):615-624.
    PubMed-indexed article2018

    Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.

    PubMedOpen PDF
  25. 25.
    Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (EINSTEIN CHOICE). N Engl J Med. 2017;376(13):1211-1222.
    PubMed-indexed article2017

    Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates.

    PubMedOpen PDF
  26. 26.
    Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration after unprovoked venous thrombosis. BMJ. 2017;356:j1065.
    PubMed-indexed article2017

    Women with a first unprovoked VTE event and none or one of the HERDOO2 criteria have a low risk of recurrent VTE and can safely discontinue anticoagulants after completing short term treatment.

    PubMedDOIOpen PDF
  27. 27.
    Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral DVT (CAVENT). Lancet. 2012;379(9810):31-38.
    PubMed-indexed article2012

    This open-label, randomised controlled trial aimed to examine whether additional treatment with catheter-directed thrombolysis using alteplase reduced development of post-thrombotic syndrome in patients with a high proximal DVT and low risk of bleeding.

    PubMedOpen PDF
  28. 28.
    Kaufman JA, Barnes GD, Chaer RA, et al. Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters. J Vasc Interv Radiol. 2020;31(10):1529-1544.e3.
    PubMed-indexed articleClinical practice guideline2020
    PubMedDOI
  29. 29.
    Mismetti P, Laporte S, Pellerin O, et al. Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism (PREPIC2). JAMA. 2015;313(16):1627-1635.
    PubMed-indexed articleRandomized controlled trial2015

    Among hospitalized patients with severe acute pulmonary embolism, the use of a retrievable inferior vena cava filter plus anticoagulation compared with anticogulation alone did not reduce the risk of symptomatic recurrent pulmonary emblism at 3 months, and these findings do not support theUse of this type of filter in patients who can be treated with antICOagulation.

    PubMedDOI
  30. 30.
    Tapson VF, Jimenez D, Nauffal D, et al. OPTALYSE PE. JACC Cardiovasc Interv. 2018;11(14):1401-1410.
    PubMed-indexed article2018

    Comparing the health status of South Australians with recent experience of caring for an adult with chronic disease with non-carers drawn from the same population found including recent as well as current carers in a population-based sample was associated with less effect on health status compared with studies focused on current carer only.

    PubMedOpen PDF
  31. 31.
    PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC randomized study. Circulation. 2005;112(3):416-422.
    PubMed-indexed article2005

    Although vena cava filters reduced the risk of pulmonary embolism but increased that of deep-vein thrombosis and had no effect on survival at 8 years, systematic use in the general population with venous thromboembolism is not recommended.

    PubMedOpen PDF
  32. 32.
    Piazza G, Hohlfelder B, Jaff MR, et al. SEATTLE II. JACC Cardiovasc Interv. 2015;8(10):1382-1392.
    PubMed-indexed article2015

    Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis decreased RV dilation, reduced pulmonary hypertension, decreased anatomic thrombus burden, and minimized intracranial hemorrhage in patients with acute massive and submassive PE.

    PubMedOpen PDF
  33. 33.
    Sista AK, Horowitz JM, Tapson VF, et al. Indigo Aspiration System for Treatment of Pulmonary Embolism: Results of the EXTRACT-PE Trial. JACC Cardiovasc Interv. 2021;14(3):319-329.
    PubMed-indexed article2021
    PubMedDOIOpen PDF
  34. 34.
    Tu T, Toma C, Tapson VF, et al. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism (FLARE). JACC Cardiovasc Interv. 2019;12(9):859-869.
    PubMed-indexed article2019

    Patients with combined pre- and post-Capillary pulmonary hypertension (CpcPH) have a poorer prognosis than patients with post-capillary PH secondary to left heart failure, and CpcPH is not as responsive to medical therapy.

    PubMedDOI
  35. 35.
    Kucher N, Boekstegers P, Müller OJ, et al. ULTIMA trial. Circulation. 2014;129(4):479-486.
    PubMed-indexed article2014

    In patients with pulmonary embolism at intermediate risk, a standardized USAT regimen was superior to anticoagulation with heparin alone in reversing RV dilatation at 24 hours, without an increase in bleeding complications.

    PubMedOpen PDF
  36. 36.
    Vedantham S, et al. ATTRACT trial – pharmacomechanical CDT vs anticoagulation for iliofemoral DVT. *NEJM*. 2017. PubMed
    PubMed-indexed article2017
    PubMedDOI
  37. 37.
    Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome (SOX): a randomised placebo-controlled trial. Lancet. 2014;383:880-888.
    PubMed-indexed articleRandomized controlled trial2014
    PubMedDOI
  38. 38.
    Raju S, et al. Endovenous iliac vein stenting for chronic venous obstruction. *J Vasc Surg*. 2010. PubMed
    PubMed-indexed article2010
    PubMedOpen PDF
  39. 39.
    Patel SS et al. Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions. European Journal of Haematology. 2022. PMID: 36192850.
    PubMed-indexed articleClinical practice guideline2022
    PubMedDOI
  40. 40.
    Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism (SOME). N Engl J Med. 2015;373(8):697-704.
    PubMed-indexed article2015

    The hypothesis that the GVHD risk correlates with the rs9277534 allele linked to the mismatched HLA-DPB1 in the recipient was tested and it was found that recipients with the high-expression allele had a high risk of GV HD.

    PubMedOpen PDF

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions